What’s Next For Vertex Pharmaceuticals Stock After An 8% Fall Last Week?

The stock price of Vertex Pharmaceuticals has seen an 8.1% drop over the last five trading days, after the company announced that it will discontinue the clinical trials for VX-864, an experimental treatment for the rare genetic disorder alpha-1 antitrypsin. Note that earlier in October 2020...